Galectin Therapeutics Inc
Galectin Therapeutics Inc (GALT) Historical Volatility
GALT's 30 day historical volatility is 74.89%, in the 28th percentile of readings over the past year. This is a low percentile, meaning Galectin Therapeutics Inc shares have been calmer than usual. GALT's 30 day implied volatility sits at 129.38%, with an IV Rank of 15.08%, leaving IV 54.49 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 18, 2026.
Read more
Tracking GALT historical volatility helps you see how much Galectin Therapeutics Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, GALT's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor GALT 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. GALT's 30 day historical volatility, or GALT HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing GALT's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis.
Historical Volatility
Historical movement is subdued versus the past year. The stock has been unusually quiet.
As of Nov 18, 2026
As of Nov 18, 2026
As of Nov 18, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →